Femke M. Prince

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Correction: Prevalence and predictors for sustained remission in rheumatoid arthritis.

Correction: Prevalence and predictors for sustained remission in rheumatoid arthritis.

Journal: PloS one

Published: August 15, 2019

Prevalence and predictors for sustained remission in rheumatoid arthritis.

Prevalence and predictors for sustained remission in rheumatoid arthritis.

Journal: PloS one

Published: July 14, 2018

S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic Arthritis.

S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic Arthritis.

Journal: The Journal of rheumatology

Published: September 22, 2017

MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis.

MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis.

Journal: Arthritis research & therapy

Published: December 17, 2014

Long-term quality of life and functional outcome of patients with juvenile idiopathic arthritis in the biologic era: a longitudinal follow-up study in the Dutch Arthritis and Biologicals in Children Register.

Long-term quality of life and functional outcome of patients with juvenile idiopathic arthritis in the biologic era: a longitudinal follow-up study in the Dutch Arthritis and Biologicals in Children Register.

Journal: Rheumatology (Oxford, England)

Published: August 11, 2014

Venous thrombosis as a first sign of SLE

Venous thrombosis as a first sign of SLE

Journal: Nederlands tijdschrift voor geneeskunde

Published: July 03, 2014

Dosing of biologics in juvenile idiopathic arthritis: is the sky the limit?

Dosing of biologics in juvenile idiopathic arthritis: is the sky the limit?

Journal: The Journal of rheumatology

Published: October 03, 2013

Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.

Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.

Journal: Annals of the rheumatic diseases

Published: September 21, 2013

Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?

Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?

Journal: Rheumatology (Oxford, England)

Published: June 07, 2013

Cost of biologics in the treatment of juvenile idiopathic arthritis: a factor not to be overlooked.

Cost of biologics in the treatment of juvenile idiopathic arthritis: a factor not to be overlooked.

Journal: Paediatric drugs

Published: April 23, 2013

Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register.

Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register.

Journal: Rheumatology (Oxford, England)

Published: December 26, 2012

Performance of matrix-based risk models for rapid radiographic progression in a cohort of patients with established rheumatoid arthritis.

Performance of matrix-based risk models for rapid radiographic progression in a cohort of patients with established rheumatoid arthritis.

Journal: Arthritis care & research

Published: July 02, 2012

Showing 1-12 of 17

Last Updated: 09/26/2026